Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure

References

• de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–615. DOI:https://doi.org/10.1016/S1470-2045(12)70137-7.
   PubMed Web of Science ®Google Scholar
• World Health Organization. GLOBAL PRIORITY LIST OF ANTIBIOTIC-RESISTANT BACTERIA TO GUIDE RESEARCH, DISCOVERY, AND DEVELOPMENT OF NEW ANTIBIOTICS [Internet]. 2017. [cited 2021 Apr 27]. Available from: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.
   Google Scholar
• Herrero R, Park JY, Forman D. The fight against gastric cancer - the IARC Working Group report. Best Pract Res Clin Gastroenterol. 2014;28(6):1107–1114.
   PubMed Web of Science ®Google Scholar
• Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–429. DOI:https://doi.org/10.1053/j.gastro.2017.04.022.
   PubMed Web of Science ®Google Scholar
• Krueger WS, Hilborn ED, Converse RR, et al. Environmental risk factors associated with Helicobacter pylori seroprevalence in the United States: a cross-sectional analysis of NHANES data. Epidemiol Infect. 2015;143(12):2520–2531. DOI:https://doi.org/10.1017/S0950268814003938.
   PubMed Web of Science ®Google Scholar
• Torres J, Correa P, Ferreccio C, et al. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. Cancer Causes Control. 2013;24(2):249–256. DOI:https://doi.org/10.1007/s10552-012-0114-8.
   PubMed Web of Science ®Google Scholar
• Subsomwong P, Miftahussurur M, Uchida T, et al. Prevalence, risk factors, and virulence genes of Helicobacter pylori among dyspeptic patients in two different gastric cancer risk regions of Thailand. PLoS One. 2017;12(10):e0187113. DOI:https://doi.org/10.1371/journal.pone.0187113.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Ramsey D, Graham D, et al., The prevalence of Helicobacter pylori remains high in African American and Hispanic veterans. Helicobacter. 2015;20(4):305–315 . DOI:https://doi.org/10.1111/hel.12199.
   PubMed Web of Science ®Google Scholar
• Harris PR, Smythies LE, Smith PD, et al. Role of childhood infection in the sequelae of H. pylori disease. Gut Microbes. 2013;4(6):426–438. DOI:https://doi.org/10.4161/gmic.26943.
   PubMed Web of Science ®Google Scholar
• Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11(6):385–399.
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–1186.
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–1315.
   PubMed Web of Science ®Google Scholar
• IARC. Heliobacter Pylori [Internet]. World Health Organization; 2018 [cited 2021 Jul 27]. Available from: https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono100B-15.pdf.
   Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht v/Florence consensus report. Gut. 2017;66(1):6–30. DOI:https://doi.org/10.1136/gutjnl-2016-312288.
   PubMed Web of Science ®Google Scholar
• Peery AF, Crockett SD, Murphy CC, et al., Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 156(1): 254–272.e11. 2019. . https://doi.org/10.1053/j.gastro.2018.08.063.
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: treatment of Helicobacter pylori Infection. Official journal of the American College of Gastroenterology [Internet]. 2017;112: https://journals.lww.com/ajg/Fulltext/2017/02000/ACG_Clinical_Guideline__Treatment_of_Helicobacter.12.aspx.
   Web of Science ®Google Scholar
• Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori Infection. Expert Review. Gastroenterology. 2021;160(5):1831–1841.https://doi.org/10.1053/j.gastro.2020.11.059
   PubMed Web of Science ®Google Scholar
• Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep. 2011;13(6):540–546.
   PubMedGoogle Scholar
• Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39(1):5–12. DOI:https://doi.org/10.1093/jac/39.1.5.
   PubMed Web of Science ®Google Scholar
• Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010;39(3):465–480.
   PubMed Web of Science ®Google Scholar
• Huang -C-C, Tsai K-W, Tsai T-J, et al. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res. 2017;5(1):23. DOI:https://doi.org/10.1186/s40364-017-0103-x.
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Pratama Putra B, Yamaoka Y. The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel). 2020;14(1):13.
   PubMedGoogle Scholar
• McNicholl AG, O’Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019;24(5):e12630. DOI:https://doi.org/10.1111/hel.12630.
   PubMed Web of Science ®Google Scholar
• Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70(10):1815–1822. DOI:https://doi.org/10.1136/gutjnl-2021-324032.
   PubMed Web of Science ®Google Scholar
• Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori–infected persons. Emerg Infect Dis. 2004;10(6):1088–1094. DOI:https://doi.org/10.3201/eid1006.030744.
   PubMed Web of Science ®Google Scholar
• Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801–807. DOI:https://doi.org/10.3904/kjim.2015.30.6.801.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr. 2010;47(1):53–58. DOI:https://doi.org/10.3164/jcbn.10-10.
   PubMed Web of Science ®Google Scholar
• Lahaie RG, Gaudreau C. Helicobacter pylori antibiotic resistance: trends over time. Can J Gastroenterol. 2000;14(10):895–899.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology. 2021;161(2):495–507.e4. DOI:https://doi.org/10.1053/j.gastro.2021.04.012.
   PubMed Web of Science ®Google Scholar
• Jonkers J. LibGuides: information Literacy History: search methods [Internet]. [cited 2020 Oct 21]. Available from: https://libguides.rug.nl/c.php?g=470628&p=3218096.
   Google Scholar
• Ramer SL. Site-ation pearl growing: methods and librarianship history and theory. J Med Libr Assoc. 2005;93(3):397–400.
   PubMed Web of Science ®Google Scholar
• Zwakman M, Verberne LM, Kars MC, et al. Introducing PALETTE: an iterative method for conducting a literature search for a review in palliative care. BMC Palliat Care. 2018;17(1):82. DOI:https://doi.org/10.1186/s12904-018-0335-z.
   PubMed Web of Science ®Google Scholar
• Liu RP, Romero R, Sarosiek J, et al., Eradication rate of Helicobacter pylori on the US-Mexico border using the urea breath test. South Med J. 111(1): 51–55. 2018. . https://doi.org/10.14423/SMJ.0000000000000747.
   PubMed Web of Science ®Google Scholar
• Argueta EA, Alsamman MA, Moss SF, et al., Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population. Gastroenterology. 160(6): 2181–2183.e1. 2021. . https://doi.org/10.1053/j.gastro.2021.02.014.
   PubMed Web of Science ®Google Scholar
• Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95(12):3393–3398. DOI:https://doi.org/10.1111/j.1572-0241.2000.03349.x.
   PubMed Web of Science ®Google Scholar
• Magaret N, Burm M, Faigel D, et al. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis. 2001;19(2):174–178. DOI:https://doi.org/10.1159/000050674.
   PubMed Web of Science ®Google Scholar
• Stevens VJ, Shneidman RJ, Johnson RE, et al. Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention. West J Med. 2002;176(2):92–96.
   PubMedGoogle Scholar
• Sullivan B, Coyle W, Nemec R, et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol. 2002;97(10):2536–2539. DOI:https://doi.org/10.1111/j.1572-0241.2002.06036.x.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jajodia P, DeGuzman L, et al. Randomized controlled trial comparing proton pump inhibitor based eradication regimen versus low-cost eradication regimen for patients with Helicobacter pylori with uninvestigated dyspepsia. J Appl Res. 2006;6(3):214–222.
   Google Scholar
• Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8(6):626–642. DOI:https://doi.org/10.1111/j.1523-5378.2003.00179.x.
   PubMed Web of Science ®Google Scholar
• Ginnebaugh BD, Baker J, Watts L, et al. S1348 triple therapy for primary treatment of Helicobacter pylori: a 19-year U.S. single center experience. Official journal of the American College of Gastroenterology | ACG. 2020;115(1):S680. DOI:https://doi.org/10.14309/01.ajg.0000707440.64691.0e
   Google Scholar
• Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106(11):1970–1975. DOI:https://doi.org/10.1038/ajg.2011.306.
   PubMed Web of Science ®Google Scholar
• Graham DY, Canaan Y, Maher J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication. Ann Intern Med. 2020;172(12):795–802. DOI:https://doi.org/10.7326/M19-3734.
   PubMed Web of Science ®Google Scholar
• Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019;64(10):2893–2898. DOI:https://doi.org/10.1007/s10620-019-05694-4.
   PubMed Web of Science ®Google Scholar
• Mertz A. Helicobacter pylori Treatment & Eradication Rates in Department of Defense Patients from 2016-2018ACG Annual Meeting [Internet]. 2020 [cited 2021 Jun 4]. Available from: https://www.eventscribe.com/2020/ACG/fsPopup.asp?Mode=presInfo&PresentationID=766539.
   Google Scholar
• Camero A, Haris M, Valadez D, et al. Su1275 – Helicobacter pylori in South Texas: eradication rates and practice trends in a university setting. Gastroenterology. 2019;156(6):S. DOI:https://doi.org/10.1016/S0016-5085(19)38200-9.
   Web of Science ®Google Scholar
• Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist. 2018;11:205–211.
   PubMed Web of Science ®Google Scholar
• Barrett-Englert M, Stern E, Keswani RN. Su1277 – the management of H. pylori is of low quality in practice due to low rates of eradication testing. Gastroenterology. 2019;156(6):S.
   Web of Science ®Google Scholar
• Rubin J, Lai A, Dulai P, et al. Su1210 - Low Rates of H. Pylori Eradication Testing and Cure Rates in Usual Care. Gastroenterology. 2018;154. S-S-504.
   Google Scholar
• Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20(1):99–107. DOI:https://doi.org/10.1111/j.1365-2036.2004.02029.x.
   PubMed Web of Science ®Google Scholar
• Tariq H, Patel H, Kamal MU, et al. Reevaluation of the efficacy of first line regimen for Helicobacter pylori. Clin Exp Gastroenterol. 2020;13:25–33.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med. 1992;116(9):705–708. DOI:https://doi.org/10.7326/0003-4819-116-9-705.
   PubMed Web of Science ®Google Scholar
• Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori–Infected Persons, United States Volume Volume 10, 6June 2004 - Emerging Infectious Diseases journal - CDC. [cited 2021 Mar 16]; Available from: https://wwwnc.cdc.gov/eid/article/10/6/03-0744_article.
   Google Scholar
• Kumar S, Sangitha R, Nachamkin I, et al. Resistance patterns of refractory Helicobacter pylori infection in a referral center in the Delaware Valley. GastroHep. 2020;2(1):6–12. DOI:https://doi.org/10.1002/ygh2.382.
   PubMedGoogle Scholar
• Dong E, Chang JI, Chen Q, et al. Su1268 – Helicobacter pylori infection: practice patterns in a community-based US healthcare system. Gastroenterology. 2019;156(6):S. DOI:https://doi.org/10.1016/S0016-5085(19)38193-4.
   Web of Science ®Google Scholar
• Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016 *Meta-analysisshowing benefits of Hp eradication for patients with PUD;4:CD003840. DOI:https://doi.org/10.1002/14651858.CD003840.pub5.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Khorrami S, Carballo F, et al. Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database of Systematic Reviews [Internet]. 2004 [cited 2021 Sep 4]; Available from: https://www.cochranelibrary.com/cdsr/doi/https://doi.org/10.1002/14651858.CD004062.pub2/full?cookiesEnabled.
   Google Scholar
• Tomtitchong P, Siribumrungwong B, Vilaichone R-K, et al. Systematic review and meta-analysis: helicobacter pylori eradication therapy after simple closure of perforated duodenal ulcer. Helicobacter. 2012;17(2):148–152. DOI:https://doi.org/10.1111/j.1523-5378.2011.00928.x.
   PubMed Web of Science ®Google Scholar
• Sonnenberg A, Turner KO, Genta RM. Low prevalence of Helicobacter pylori-positive peptic ulcers in private outpatient endoscopy centers in the United States. Am J Gastroenterol. 2020;115(2):244–250.
   PubMed Web of Science ®Google Scholar
• Shiota S, Thrift AP, Green L, et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol. 2017;15(7):1037–1046.e3. DOI:https://doi.org/10.1016/j.cgh.2017.01.006.
   PubMed Web of Science ®Google Scholar
• Parbhu SK, Cole GG, Fang JC, et al. Su1252 – incident diagnoses of gastric intestinal metaplasia in the us: patient characteristics, egd findings, and clinical practice patterns at a large us tertiary care center. Gastroenterology. 2019;156(6):S. DOI:https://doi.org/10.1016/S0016-5085(19)38178-8.
   Web of Science ®Google Scholar
• Kligman G, Szafron D, Ali H, et al. Su1247 – screening for gastric intestinal metaplasia: what to consider and whom to screen. Gastroenterology. 2019;156(6):S. DOI:https://doi.org/10.1016/S0016-5085(19)38173-9.
   Web of Science ®Google Scholar
• Huang RJ, Ende AR, Singla A, et al., Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. Gastrointest Endosc. 91(1): 70–77. 2020. . https://doi.org/10.1016/j.gie.2019.07.038.
   PubMed Web of Science ®Google Scholar
• Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158(3):527–536.e7. DOI:https://doi.org/10.1053/j.gastro.2019.10.019.
   PubMed Web of Science ®Google Scholar
• Fansiwala K, Liang PS. S1353 risk factors for gastric cancer in a veteran population. Official journal of the American College of Gastroenterology. 2020;115(1):S682.https://doi.org/10.14309/01.ajg.0000707460.70708.51
   Google Scholar
• Li D, Jiang S, Postlethwaite D, et al. Incidence of noncardia gastric adenocarcinoma after Helicobacter pylori eradication in a large diverse US population. Gastroenterology. 2020;158:S-185-S-186.
   Web of Science ®Google Scholar
• Dhingra R, Natov NS, Daaboul Y, et al. Increased risk of progression to gastric adenocarcinoma in patients with non-dysplastic gastric intestinal metaplasia versus a control population. Dig Dis Sci. 2020;65(11):3316–3323. DOI:https://doi.org/10.1007/s10620-019-06031-5.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Mallepally N, Hammad T, et al. Prevalence of Helicobacter pylori positive non-cardia gastric adenocarcinoma is low and decreasing in a US population. Dig Dis Sci. 2020;65(8):2403–2411. DOI:https://doi.org/10.1007/s10620-019-05955-2.
   PubMed Web of Science ®Google Scholar
• Li D, Bautista MC, Jiang S-F, et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111(8):1104–1113. DOI:https://doi.org/10.1038/ajg.2016.188.
   PubMed Web of Science ®Google Scholar
• Reddy KM, Chang JI, Shi JM, et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US. Integrated Health Care System. Clinical Gastroenterology and Hepatology. 2016;14(10):1420–1425. DOI:https://doi.org/10.1016/j.cgh.2016.05.045
   PubMed Web of Science ®Google Scholar
• Everhart JE, Kruszon-Moran D, Perez-Perez GI, et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis. 2000;181(4):1359–1363. DOI:https://doi.org/10.1086/315384.
   PubMed Web of Science ®Google Scholar
• Shah SC, McKinley M, Gupta S, et al., Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older. Gastroenterology. 159(5): 1705–1714. 2020. . https://doi.org/10.1053/j.gastro.2020.07.049.
   PubMed Web of Science ®Google Scholar
• Anderson WF, Rabkin CS, Turner N, et al. The changing face of noncardia gastric cancer incidence among us non-Hispanic whites. J Natl Cancer Inst. 2018;110(6):608–615. DOI:https://doi.org/10.1093/jnci/djx262.
   PubMedGoogle Scholar
• Gupta S, Tao L, Murphy JD, et al. Race/ethnicity, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology. 2019;156(1):59–62.e4. DOI:https://doi.org/10.1053/j.gastro.2018.09.045.
   PubMed Web of Science ®Google Scholar
• Holowatyj AN, Ulrich CM, Lewis MA. Racial/ethnic patterns of young-onset noncardia gastric cancer. Cancer Prev Res (Phila). 2019;12(11):771–780.
   PubMed Web of Science ®Google Scholar
• Duma N, Sanchez LJ, Castro YS, et al. Gastric adenocarcinoma: clinicopathologic differences among Hispanics and non-Hispanic whites. A single Institution’s experience over 14 years. Ann Gastroenterol. 2016;29(3):325–331. DOI:https://doi.org/10.20524/aog.2016.0030.
   PubMedGoogle Scholar
• Wang Z, El-Serag HB, Thrift AP. Increasing incidence of advanced non-cardia gastric cancers among younger hispanics in the USA. Dig Dis Sci. 2021;66(5):1669–1672.
   PubMed Web of Science ®Google Scholar
• Laszkowska M, Tramontano AC, Kim J, et al. Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma. Cancer Med. 2020;9(15):5678–5686. DOI:https://doi.org/10.1002/cam4.3063.
   PubMed Web of Science ®Google Scholar
• Klapheke AK, Carvajal-Carmona LG, Cress RD. Racial/ethnic differences in survival among gastric cancer patients in California. Cancer Causes Control. 2019;30(7):687–696.
   PubMed Web of Science ®Google Scholar
• Ulanja MB, Beutler BD, Rishi M, et al. Influence of race and geographic setting on the management of gastric adenocarcinoma. J Surg Oncol. 2019;120(2):270–279. DOI:https://doi.org/10.1002/jso.25503.
   PubMed Web of Science ®Google Scholar
• Ikoma N, Cormier JN, Feig B, et al. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018;124(5):998–1007. DOI:https://doi.org/10.1002/cncr.31155.
   PubMed Web of Science ®Google Scholar
• Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010;123(4):358–366.e2.
   PubMed Web of Science ®Google Scholar
• Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther. 2011;33(5):585–591. DOI:https://doi.org/10.1111/j.1365-2036.2010.04563.x.
   PubMed Web of Science ®Google Scholar
• Kanotra R, Ahmed M, Patel N, et al. Seasonal variations and trends in hospitalization for peptic ulcer disease in the United States: a 12-year analysis of the nationwide inpatient sample. Cureus [Internet]. [cited 2021 May 26];8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130352/.
   PubMedGoogle Scholar
• Al-Jashaami L, Al-Zubaidi YA, Boddu S, et al. Helicobacter pylori-associated ulcers and related hospitalizations are common at a safety net hospital in Arizona: 937. Official journal of the American College of Gastroenterology | ACG. 2016; 111: S406. https://doi.org/10.14309/00000434-201610001-00937
   Web of Science ®Google Scholar
• Viviane A, Alan BN. Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health. 2008;11(1):1–3.
   PubMed Web of Science ®Google Scholar
• Bernica J, Cole R, Flores A, et al. HP QI abstract: improving helicobacter pylori testing in patients with acute upper gi bleeding due to peptic ulcer disease. Gastroenterology. 2020;159(2):e22–e23. DOI:https://doi.org/10.1053/j.gastro.2020.06.060.
   Web of Science ®Google Scholar
• Havens JM, Castillo-Angeles M, Nitzschke SL, et al. Disparities in peptic ulcer disease: a nationwide study. Am J Surg. 2018;216(6):1127–1128. DOI:https://doi.org/10.1016/j.amjsurg.2018.08.025.
   PubMed Web of Science ®Google Scholar
• Olufajo OA, Wilson A, Yehayes B, et al. Trends in the surgical management and outcomes of complicated peptic ulcer disease. Am Surg. 2020;86(7):856–864. DOI:https://doi.org/10.1177/0003134820939929.
   PubMed Web of Science ®Google Scholar
• Wright GP, Davis AT, Koehler TJ, et al. Cost-efficiency and outcomes in the treatment of perforated peptic ulcer disease: laparoscopic versus open approach. Surgery. 2014;156(4):1003–1007. DOI:https://doi.org/10.1016/j.surg.2014.06.047.
   PubMed Web of Science ®Google Scholar
• Søreide K. Sepsis drives the cost in perforated peptic ulcer. Surgery. 2015;158(1):312–313.
   PubMed Web of Science ®Google Scholar
• Lee KC, Sturgeon D, Lipsitz S, et al. Mortality and health care utilization among medicare patients undergoing emergency general surgery vs those with acute medical conditions. JAMA Surg. 2020;155(3):216–223. DOI:https://doi.org/10.1001/jamasurg.2019.5087.
   PubMed Web of Science ®Google Scholar
• Hall MJ, Williams SN, DeFrances CJ, et al. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief. 2011;62:1–8.
   PubMedGoogle Scholar
• Siddiqui AH, Ahmed M, Khan TMA, et al. Trends and outcomes of gastrointestinal bleeding among septic shock patients of the United States: a 10-Year Analysis of a Nationwide Inpatient Sample. Cureus. 2020;12(5):e8029. DOI:https://doi.org/10.7759/cureus.8029.
   PubMed Web of Science ®Google Scholar
• Cancer of the Stomach - Cancer Stat Facts. [Internet]SEER. [cited 2021 Mar 12]. Available from: https://seer.cancer.gov/statfacts/html/stomach.html.
   Google Scholar
• Solanki S, Chakinala RC, Haq KF, et al. Inpatient burden of gastric cancer in the United States. Ann Transl Med Internet]. 2019 [cited 2021 Jun 15];7. https://doi.org/10.21037/atm.2019.11.54
   Google Scholar
• Sarvepalli S, Garg SK, Sarvepalli SS, et al. Hospital utilization in patients with gastric cancer and factors affecting in-hospital mortality, length of stay, and costs. J Clin Gastroenterol. 2019;53(4):e157–e163. DOI:https://doi.org/10.1097/MCG.0000000000001016.
   PubMed Web of Science ®Google Scholar
• Liu D, Mehta D, Kaur S, et al. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018;11(1):138. DOI:https://doi.org/10.1186/s13045-018-0682-5.
   PubMed Web of Science ®Google Scholar
• Karve S, Lorenzo M, Liepa AM, et al. Treatment patterns, costs, and survival among medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015;15(2):87–104. DOI:https://doi.org/10.5230/jgc.2015.15.2.87.
   PubMed Web of Science ®Google Scholar
• Trumbull D, Lemini R, Elli F, et al. Age-based trends of gastric adenocarcinoma in the United States. Am Surg. 2020;86(5):407–414. DOI:https://doi.org/10.1177/0003134820918250.
   PubMed Web of Science ®Google Scholar
• Hess LM, Michael D, Mytelka DS, et al. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer. 2016;19(2):607–615. DOI:https://doi.org/10.1007/s10120-015-0486-z.
   PubMed Web of Science ®Google Scholar
• Sherman KL, Merkow RP, Shah AM, et al. Assessment of advanced gastric cancer management in the United States. Ann Surg Oncol. 2013;20(7):2124–2131. DOI:https://doi.org/10.1245/s10434-013-2953-2.
   PubMed Web of Science ®Google Scholar
• Hirst C, Ryan J, Tunceli O, et al. Cost profile of patients with gastric cancer using United States Administrative Claims Data. Value Health. 2014;17(3):A78. DOI:https://doi.org/10.1016/j.jval.2014.03.457.
   Web of Science ®Google Scholar
• Murakami TT, Scranton RA, Brown HE, et al. Management of helicobacter pylori in the United States: results from a national survey of gastroenterology physicians. Prev Med. 2017;100:216–222.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102(2):493–496. DOI:https://doi.org/10.1016/0016-5085(92)90095-G.
   PubMed Web of Science ®Google Scholar
• Kuo C-H, C-y L, Shih H-Y, et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029–16036. DOI:https://doi.org/10.3748/wjg.v20.i43.16029.
   PubMed Web of Science ®Google Scholar
• Martis S, Peter I, Hulot J-S, et al. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J. 2013;13(4):369–377. DOI:https://doi.org/10.1038/tpj.2012.10.
   PubMed Web of Science ®Google Scholar
• Malnick SDH, Melzer E, Attali M, et al. Helicobacter pylori: friend or foe? World J Gastroenterol. 2014;20(27):8979–8985. DOI:https://doi.org/10.3748/wjg.v20.i27.8979.
   PubMed Web of Science ®Google Scholar
• Shah S, Shah S, Halvorson A, et al. Helicobacter pylori eradication therapy is not associated with increased cardiovascular mortality: a propensity score weighted analysis of a national veteran cohort. Gastro Hep Adv. 2021;1:25–28. DOI:https://doi.org/10.1016/j.gastha.2021.10.003.
   Google Scholar
• Kumar S, Metz DC, Kaplan DE, et al. Treatment of Helicobacter pylori is not associated with future Clostridium difficile infection. Am J Gastroenterol. 2020;115(5):716–722. DOI:https://doi.org/10.14309/ajg.0000000000000626.
   PubMed Web of Science ®Google Scholar
• Shah SC, Tepler A, Chung CP, et al. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis. Gastroenterology. 2021;161(5):1443–1459. DOI:https://doi.org/10.1053/j.gastro.2021.07.043.
   PubMed Web of Science ®Google Scholar
• Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382(5):427–436. DOI:https://doi.org/10.1056/NEJMoa1909666.
   PubMed Web of Science ®Google Scholar
• Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085–1095. DOI:https://doi.org/10.1056/NEJMoa1708423.
   PubMed Web of Science ®Google Scholar